NYSE · Financial Statements

Merck & Company, Inc. (MRK) Revenue, Earnings & Financial Statements

$145.57 NYSE: MRK Market Cap $358.87B

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

Merck & Company, Inc. most recently reported annual revenue of $64.9B, net profit of $18.3B. Revenue grew at an average annual rate of 9.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Merck & Company, Inc.: Revenue rose from $39.8B in 2016 to $64.9B in 2025, a change of +63.1% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 13.8% to 36.2%, a shift of +22.4 percentage points; the most recent year shows net profit of $18.3B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$39.8B$40.1B$42.3B$39.1B$41.5B$48.7B$59.3B$60.1B$64.2B$64.9B
Operating Expenses$34.3B$33.3B$33.4B$31.2B$36.0B$35.5B$41.0B$57.2B$43.9B$41.4B
Operating Profit$5.5B$6.8B$8.9B$7.9B$5.5B$13.2B$18.3B$3.0B$20.2B$23.5B
Operating Margin13.8%16.9%21.1%20.3%13.4%27.1%30.8%4.9%31.5%36.2%
Other Income−$840.0M−$276.0M−$230.0M−$755.0M$315.0M$680.0M−$1.8B−$1.1B−$285.0M−$2.4B
Interest$693.0M$754.0M$772.0M$893.0M$831.0M$806.0M$962.0M$1.1B$1.3B$1.4B
Depreciation$5.5B$4.7B$4.5B$3.7B$3.5B$3.2B$3.9B$3.9B$4.5B$5.8B
Profit Before Tax$4.7B$6.5B$8.7B$7.2B$5.9B$13.9B$16.4B$1.9B$19.9B$21.1B
Tax rate (%)15.4%62.9%28.8%21.8%22.9%11.0%11.7%80.0%14.1%13.3%
Net Profit$3.9B$2.4B$6.2B$9.8B$7.1B$13.0B$14.5B$365.0M$17.1B$18.3B
EPS$2.04$0.93$2.32$3.82$2.78$5.14$5.71$0.14$6.74$7.28

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$16.0B$14.6B$15.8B$16.1B$16.7B$15.6B$15.6B$15.8B$17.2B$16.3B$16.3B$16.6B
Operating Expenses$10.1B$16.3B$10.0B$10.0B$12.7B$11.3B$8.9B$9.4B$9.7B$10.2B$18.2B$17.3B
Operating Profit$5.9B−$1.7B$5.8B$6.1B$4.0B$4.3B$6.7B$6.4B$7.5B$6.2B−$1.9B−$683.0M
Operating Margin36.8%-11.7%36.5%38.0%23.9%27.8%43.0%40.3%43.4%37.7%-11.6%-4.1%
Interest$317.0M$310.0M$303.0M$310.0M$330.0M$328.0M$313.0M$305.0M$327.0M$411.0M$0$525.0M
Profit Before Tax$5.6B−$2.0B$5.7B$6.0B$4.1B$4.2B$5.9B$5.0B$6.7B$3.4B−$3.5B−$683.0M
Tax rate (%)15.5%40.1%15.9%9.1%22.7%10.2%13.9%11.4%14.2%13.4%-20.1%-95.8%
Net Profit$4.7B−$1.2B$4.8B$5.5B$3.2B$3.7B$5.1B$4.4B$5.8B$3.0B−$4.2B−$1.3B
EPS$1.86−$0.48$1.87$2.14$1.24$1.48$2.01$1.76$2.32$1.19−$1.72−$0.54

Over the 10 years reported for Merck & Company, Inc., borrowings increased from $24.8B in 2016 to $50.5B in 2025, cash stood at $14.6B in the latest year, shareholders' equity was $1.8B, current assets covered current liabilities 1.54 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$95.4B$87.9B$82.6B$84.4B$91.6B$105.7B$109.2B$106.7B$117.1B$136.9B
Current Assets$30.6B$24.8B$25.9B$27.5B$27.8B$30.3B$35.7B$32.2B$38.8B$43.5B
Cash$6.5B$6.1B$8.0B$9.7B$8.1B$8.1B$12.7B$6.8B$13.2B$14.6B
Inventory$4.9B$5.1B$5.4B$6.0B$5.6B$6.0B$5.9B$6.4B$6.1B$6.7B
Receivables$7.0B$6.9B$7.1B$6.8B$6.8B$9.2B$9.4B$10.3B$10.3B$12.7B
Fixed Assets$12.0B$12.4B$13.3B$15.1B$17.0B$19.3B$21.4B$23.1B$23.8B$26.8B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$19.2B$14.5B$7.1B$2.2B$785.0M$370.0M$1.5B$504.0M$910.0M$2.2B
Other Assets$18.2B$18.3B$18.3B$19.4B$18.9B$21.3B$21.2B$21.2B$21.7B$21.6B
Total Liabilities$55.1B$53.3B$55.8B$58.4B$66.2B$67.4B$63.1B$69.0B$70.7B$84.2B
Current Liabilities$17.2B$18.6B$22.2B$22.2B$27.3B$23.9B$24.2B$25.7B$28.4B$28.3B
Borrowings$24.8B$24.4B$25.1B$27.4B$33.4B$34.6B$32.0B$36.3B$38.3B$50.5B
Other Liabilities$30.2B$28.9B$30.6B$31.0B$32.8B$32.8B$31.1B$32.8B$32.5B$33.7B
Equity$1.8B$1.8B$1.8B$1.8B$1.8B$1.8B$1.8B$1.8B$1.8B$1.8B
Reserves$40.1B$34.3B$26.7B$25.9B$25.3B$38.2B$46.0B$37.6B$46.3B$52.6B

For Merck & Company, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $12.4B; free cash flow was positive in 10 of 10 years; financing activities used $5.2B in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$10.4B$6.4B$10.9B$13.4B$10.3B$14.1B$19.1B$13.0B$21.5B$16.5B
Investing Cash Flow−$4.8B$791.0M$1.7B−$6.1B−$13.9B−$21.0B−$9.3B−$17.9B−$11.1B−$17.9B
Financing Cash Flow−$2.6B−$3.7B−$8.8B−$4.4B−$1.6B$7.6B−$240.0M−$1.5B−$1.5B−$5.2B
Net Cash Flow−$2.0B−$423.0M$1.9B$2.0B−$1.8B$14.0M$4.6B−$5.9B$6.4B$1.4B
Free Cash Flow$8.8B$4.6B$8.3B$10.0B$5.8B$9.7B$14.7B$9.1B$18.1B$12.4B

Valuation & Return Ratios

MetricValue
PEG Ratio-1.43
EV / EBITDA29.12
FCF Yield4.48%
Quick Ratio1.10
Interest Coverage8.75
Return 1Y63.67%
Return 3Y58.48%
Return 5Y104.17%

Merck & Company, Inc. (MRK) financials — frequently asked questions

What is Merck & Company, Inc.'s annual revenue?

Merck & Company, Inc. (MRK) reported annual revenue of $64.9B in its most recent fiscal year.

What is Merck & Company, Inc.'s net profit?

Merck & Company, Inc. (MRK) reported net profit of $18.3B in its most recent fiscal year.

What is MRK EV/EBITDA?

Merck & Company, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 29.12.

Revenue and earnings of other Drug Manufacturers - General stocks

LLY revenue $65.2BJNJ revenue $94.2BABBV revenue $61.2BNVS revenue $54.8BAZN revenue $58.7BAMGN revenue $36.7BGILD revenue $29.4BNVO revenue $309.1BPFE revenue $62.6BBMY revenue $48.2BAll Drug Manufacturers - General stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
MRK Overview MRK Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.